{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:21:55Z","timestamp":1794547315151,"version":"4.9.1"},"reference-count":65,"publisher":"American Chemical Society (ACS)","issue":"20","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100018555","name":"Science and Technology Program of Guizhou Province","doi-asserted-by":"publisher","award":["ZK-2024-Key-097"],"award-info":[{"award-number":["ZK-2024-Key-097"]}],"id":[{"id":"10.13039\/501100018555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009620","name":"Science and Technology Department of Gansu Province","doi-asserted-by":"publisher","award":["24ZDFA002"],"award-info":[{"award-number":["24ZDFA002"]}],"id":[{"id":"10.13039\/501100009620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2025JYCXJJ067"],"award-info":[{"award-number":["2025JYCXJJ067"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Research and Development Program of Gansu Province","award":["23YFFA0007"],"award-info":[{"award-number":["23YFFA0007"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Camptothecin (CPT), a classical topoisomerase I (TOP I) inhibitor, shows potent antitumor activity but is limited by toxicity and lactone instability. Herein, structural optimization of the CPT scaffold was conducted via A-ring fluorination and C-7 and C-17 modifications. A series of fluorinated derivatives were synthesized and evaluated for antiproliferative activity. Structure\u2212activity relationship studies identified C-11 fluorination as optimal, whereas C-7 ethyl and C-17 thiocarbonyl substitutions enhanced potency. Compounds W3 (11F-CPT) and W12 (7Et-11F-CPT) exhibited potential inhibitory effects against pancreatic cancer cells (PANC-1 and BxPC-3) and were selected for further study. Both compounds demonstrated potent antitumor activity in vitro and in vivo with improved stability and safety. Mechanistic studies have indicated that they induce cell cycle arrest and apoptosis and inhibit TOP I activity. These findings clarify the effects of fluorination on CPT activity and support its potential use in pancreatic cancer, thereby providing guidance for scaffold optimization.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01583","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:02:59Z","timestamp":1790355779000},"page":"24030-24052","source":"Crossref","is-referenced-by-count":0,"title":["Design, Synthesis, and Biological Evaluation of Novel, Fluorinated Camptothecin Derivatives as Potential Topoisomerase I Inhibitors"],"prefix":"10.1021","volume":"69","author":[{"given":"Gui-Sha","family":"Chen","sequence":"first","affiliation":[{"name":"Lanzhou University , , ,","place":["Lanzhou, People\u2019s Republic of China, 730000"]},{"name":"Huazhong University of Science and Technology , , ,","place":["Wuhan, People\u2019s Republic of China, 430030"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng-Tuo","family":"Wang","sequence":"additional","affiliation":[{"name":"Lanzhou University , , ,","place":["Lanzhou, People\u2019s Republic of China, 730000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong-Fei","family":"Luo","sequence":"additional","affiliation":[{"name":"Lanzhou University , , ,","place":["Lanzhou, People\u2019s Republic of China, 730000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[{"name":"Lanzhou University , , ,","place":["Lanzhou, People\u2019s Republic of China, 730000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Yan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology , , ,","place":["Wuhan, People\u2019s Republic of China, 430030"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Liang","family":"Mou","sequence":"additional","affiliation":[{"name":"Lanzhou University , , ,","place":["Lanzhou, People\u2019s Republic of China, 730000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Li","family":"Dai","sequence":"additional","affiliation":[{"name":"Lanzhou University , , ,","place":["Lanzhou, People\u2019s Republic of China, 730000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Ping","family":"Gao","sequence":"additional","affiliation":[{"name":"Lanzhou University , , ,","place":["Lanzhou, People\u2019s Republic of China, 730000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Qi","family":"Pan","sequence":"additional","affiliation":[{"name":"Lanzhou University , , ,","place":["Lanzhou, People\u2019s Republic of China, 730000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Lanzhou University , , ,","place":["Lanzhou, People\u2019s Republic of China, 730000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan-Ke","family":"Li","sequence":"additional","affiliation":[{"name":"Lanzhou University , , ,","place":["Lanzhou, People\u2019s Republic of China, 730000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3225-4083","authenticated-orcid":true,"given":"Chuan-Rui","family":"Xu","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology , , ,","place":["Wuhan, People\u2019s Republic of China, 430030"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology , , ,","place":["Wuhan, People\u2019s Republic of China, 430030"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3055-3426","authenticated-orcid":true,"given":"Zhi-Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Lanzhou University , , ,","place":["Lanzhou, People\u2019s Republic of China, 730000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5600-0913","authenticated-orcid":true,"given":"Ying-Qian","family":"Liu","sequence":"additional","affiliation":[{"name":"Lanzhou University , , ,","place":["Lanzhou, People\u2019s Republic of China, 730000"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"2026102305074360700_cit1","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41571-021-00514-z","article-title":"Planning for tomorrow: global cancer incidence and the role of prevention 2020\u22122070","volume":"18","author":"Soerjomataram","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026102305074360700_cit2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"Ca-Cancer J. Clin."},{"key":"2026102305074360700_cit3","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1200\/jco.2015.64.0730","article-title":"Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers","volume":"34","author":"Vasen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"2026102305074360700_cit4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","article-title":"Optimizing the outcomes of pancreatic cancer surgery","volume":"16","author":"Strobel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026102305074360700_cit5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13304-021-01186-1","article-title":"Neoadjuvant therapy for pancreatic cancer","volume":"74","author":"Gugenheim","year":"2022","journal-title":"Updat. Surg."},{"key":"2026102305074360700_cit6","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/nejmoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2026102305074360700_cit7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/nejmoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2026102305074360700_cit8","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1021\/ja00968a057","article-title":"Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor fromCamptotheca acuminata1,2","volume":"88","author":"Wall","year":"1966","journal-title":"J. Am. Chem. Soc."},{"key":"2026102305074360700_cit9","doi-asserted-by":"publisher","first-page":"14873","DOI":"10.1016\/s0021-9258(17)38654-4","article-title":"Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I","volume":"260","author":"Hsiang","year":"1985","journal-title":"J. Biol. Chem."},{"key":"2026102305074360700_cit10","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/0959-8049(96)00291-2","article-title":"Future Directions for Clinical Research With CPT-11 (Irinotecan)","volume":"32","author":"Von Hoff","year":"1996","journal-title":"Eur. J. Cancer"},{"key":"2026102305074360700_cit11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lungcan.2010.05.020","article-title":"Therapy of small cell lung cancer with emphasis on oral topotecan","volume":"70","author":"Pirker","year":"2010","journal-title":"Lung Cancer"},{"key":"2026102305074360700_cit12","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3390\/ijms22031223","article-title":"Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer","volume":"22","author":"Hur","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"2026102305074360700_cit13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/s0169-5002(03)00190-9","article-title":"Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer","volume":"41","author":"Braybrooke","year":"2003","journal-title":"Lung Cancer"},{"key":"2026102305074360700_cit14","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/cncr.20132","article-title":"Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia","volume":"100","author":"Giles","year":"2004","journal-title":"Cancer"},{"key":"2026102305074360700_cit15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jchromb.2014.01.017","article-title":"Development and validation of a sensitive LC-MS\/MS method for simultaneous quantification of sinotecan and its active metabolite in human blood","volume":"951\u2212952","author":"Yu","year":"2014","journal-title":"J. Chromatogr., B"},{"key":"2026102305074360700_cit16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00280-007-0592-7","article-title":"Phase II study of rubitecan in recurrent or metastatic head and neck cancer","volume":"62","author":"Caponigro","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2026102305074360700_cit17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10637-005-2464-5","article-title":"Pre-irradiation 9-Amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme","volume":"24","author":"Farray","year":"2005","journal-title":"Invest. New Drugs"},{"key":"2026102305074360700_cit18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41419-018-0700-0","article-title":"A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo","volume":"9","author":"Zou","year":"2018","journal-title":"Cell Death Dis."},{"key":"2026102305074360700_cit19","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1215\/15228517-2008-030","article-title":"Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas","volume":"10","author":"Grossman","year":"2008","journal-title":"Neuro Oncol."},{"key":"2026102305074360700_cit20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1517\/13543780802571674","article-title":"Diflomotecan , a promising homocamptothecin for cancer therapy","volume":"18","author":"Kroep","year":"2009","journal-title":"Expert Opin. Invest. Drugs"},{"key":"2026102305074360700_cit21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00280-012-1906-y","article-title":"Population pharmacokinetic\/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors","volume":"70","author":"Troco\u0301niz","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2026102305074360700_cit22","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1158\/1078-0432.ccr-06-1277","article-title":"Chimmitecan, a Novel 9-Substituted Camptothecin, with Improved Anticancer Pharmacologic ProfilesIn vitroandIn vivo","volume":"13","author":"Huang","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"2026102305074360700_cit23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.phrs.2009.07.005","article-title":"Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91","volume":"61","author":"Yeh","year":"2010","journal-title":"Pharmacol. Res."},{"key":"2026102305074360700_cit24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.bcp.2009.09.012","article-title":"Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma","volume":"79","author":"Zuco","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"2026102305074360700_cit25","doi-asserted-by":"publisher","first-page":"833583","DOI":"10.3389\/fphar.2022.833583","article-title":"A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil\/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"2026102305074360700_cit26","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.3390\/ijms13055498","article-title":"Metabolic Difference of CZ48 in Human and Mouse Liver Microsomes","volume":"13","author":"Liu","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"2026102305074360700_cit27","first-page":"1000","article-title":"Effect of HM910, a novel camptothecin derivative, on the inhibition of multiple myeloma cell growth in vitro and in vivo","volume":"5","author":"Li","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"2026102305074360700_cit28","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1021\/jm010893l","article-title":"Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents","volume":"44","author":"Lerchen","year":"2001","journal-title":"J. Med. Chem."},{"key":"2026102305074360700_cit29","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3390\/cancers13061218","article-title":"Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy","volume":"13","author":"Huang","year":"2021","journal-title":"Cancers"},{"key":"2026102305074360700_cit30","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1158\/1078-0432.703.11.2","article-title":"Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors","volume":"11","author":"Soepenberg","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"2026102305074360700_cit31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/s0168-3659(01)00323-6","article-title":"Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo","volume":"74","author":"Singer","year":"2001","journal-title":"J. Controlled Release"},{"key":"2026102305074360700_cit32","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/s1470-2045(15)00332-0","article-title":"Etirinotecan pegol (NKTR-102) versus treatment of physician\u2019s choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial","volume":"16","author":"Perez","year":"2015","journal-title":"Lancet Oncol."},{"key":"2026102305074360700_cit33","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1021\/acs.jced.5b00994","article-title":"Measurement and Correlation of the Solubility for Camptothecine in Different Organic Solvents","volume":"61","author":"Zhi","year":"2016","journal-title":"J. Chem. Eng. Data"},{"key":"2026102305074360700_cit34","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/humu.24418","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"43","author":"Dean","year":"2022","journal-title":"Hum. Mutat."},{"key":"2026102305074360700_cit35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrc2789","article-title":"ABC transporters in cancer: more than just drug efflux pumps","volume":"10","author":"Fletcher","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"2026102305074360700_cit36","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1158\/0008-5472.can-10-2726","article-title":"Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma","volume":"71","author":"Paillas","year":"2011","journal-title":"Cancer Res."},{"key":"2026102305074360700_cit37","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.2147\/ott.s240803","article-title":"Irinotecan Induces Autophagy-Dependent Apoptosis and Positively Regulates ROS-Related JNK- and P38-MAPK Pathways in Gastric Cancer Cells","volume":"13","author":"Zhu","year":"2020","journal-title":"OncoTargets Ther."},{"key":"2026102305074360700_cit38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.bbrc.2009.09.066","article-title":"Induction of oncogene addiction shift to NF-\u03baB by camptothecin in solid tumor cells","volume":"390","author":"Togano","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2026102305074360700_cit39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bcp.2011.09.021","article-title":"Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition","volume":"83","author":"Perego","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"2026102305074360700_cit40","doi-asserted-by":"publisher","first-page":"44758","DOI":"10.18632\/oncotarget.5815","article-title":"Radiation and SN38 treatments modulate the expression of microRNAs, cytokines and chemokines in colon cancer cells in a p53-directed manner","volume":"6","author":"Pathak","year":"2015","journal-title":"Oncotarget"},{"key":"2026102305074360700_cit41","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3389\/fimmu.2020.01280","article-title":"Cancer Stem Cells\ue5f8Origins and Biomarkers: Perspectives for Targeted Personalized Therapies","volume":"11","author":"Walcher","year":"2020","journal-title":"Front. Immunol."},{"key":"2026102305074360700_cit42","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1021\/acs.jmedchem.0c01516","article-title":"A Decade of FDA-Approved Drugs (2010\u22122019): Trends and Future Directions","volume":"64","author":"Brown","year":"2021","journal-title":"J. Med. Chem."},{"key":"2026102305074360700_cit43","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3390\/cells12071034","article-title":"An Efficient Humanized Mouse Model for Oral Anti-Retroviral Administration","volume":"12","author":"Virdi","year":"2023","journal-title":"Cells"},{"key":"2026102305074360700_cit44","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1158\/1078-0432.ccr-20-0156","article-title":"5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers\ue5f8Letter","volume":"26","author":"Maeda","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"2026102305074360700_cit45","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13643-022-02134-9","article-title":"Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis","volume":"11","author":"Yuan","year":"2022","journal-title":"Syst. Rev."},{"key":"2026102305074360700_cit46","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/nejmoa1917239","article-title":"KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026102305074360700_cit47","doi-asserted-by":"publisher","first-page":"17588359251317846","DOI":"10.1177\/17588359251317846","article-title":"Belzutifan for the treatment of renal cell carcinoma","volume":"17","author":"Wu","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2026102305074360700_cit48","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s11523-023-01002-3","article-title":"Ivosidenib: A Review in Advanced Cholangiocarcinoma","volume":"18","author":"Frampton","year":"2023","journal-title":"Targeted Oncol."},{"key":"2026102305074360700_cit49","doi-asserted-by":"publisher","first-page":"16589","DOI":"10.1021\/acs.jmedchem.2c01422","article-title":"Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3K\u03b1","volume":"65","author":"Hanan","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026102305074360700_cit50","doi-asserted-by":"publisher","first-page":"121105","DOI":"10.1016\/j.lfs.2022.121105","article-title":"Anti-tumor effects and mechanism of a novel camptothecin derivative YCJ100","volume":"311","author":"Zhang","year":"2022","journal-title":"Life Sci."},{"key":"2026102305074360700_cit51","doi-asserted-by":"publisher","first-page":"106652","DOI":"10.1016\/j.bioorg.2023.106652","article-title":"Improved anti-tumor activity of fluorinated camptothecin derivatives 9-fluorocamptothecin and 7-ethyl-9-fluorocamptothecin on hepatocellular carcinoma by targeting topoisomerase I","volume":"139","author":"Zhang","year":"2023","journal-title":"Bioorg. Chem."},{"key":"2026102305074360700_cit52","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1021\/acs.jmedchem.3c02115","article-title":"Unleashing the Potential of Camptothecin: Exploring Innovative Strategies for Structural Modification and Therapeutic Advancements","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026102305074360700_cit53","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.bmc.2003.11.036","article-title":"Camptothecin: current perspectives","volume":"12","author":"Thomas","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"2026102305074360700_cit54","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/med.21342","article-title":"Perspectives on Biologically Active Camptothecin Derivatives","volume":"35","author":"Liu","year":"2015","journal-title":"Med. Res. Rev."},{"key":"2026102305074360700_cit55","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.2174\/092986706777585004","article-title":"Review Camptothecin: Current Perspectives","volume":"13","author":"Li","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"2026102305074360700_cit56","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1021\/jm8001982","article-title":"Thiocamptothecin","volume":"51","author":"Samori\u0300","year":"2008","journal-title":"J. Med. Chem."},{"key":"2026102305074360700_cit57","doi-asserted-by":"publisher","first-page":"113639","DOI":"10.1016\/j.ejmech.2021.113639","article-title":"Camptothecin\u2019s journey from discovery to WHO Essential Medicine: Fifty years of promise","volume":"223","author":"Khaiwa","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"2026102305074360700_cit58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0014-4827(91)90534-2","article-title":"The S-phase cytotoxicity of camptothecin","volume":"193","author":"Del Bino","year":"1991","journal-title":"Exp. Cell Res."},{"key":"2026102305074360700_cit59","first-page":"5016","article-title":"Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I","volume":"49","author":"Covey","year":"1989","journal-title":"Cancer Res."},{"key":"2026102305074360700_cit60","doi-asserted-by":"publisher","first-page":"15387","DOI":"10.1073\/pnas.242259599","article-title":"The mechanism of topoisomerase I poisoning by a camptothecin analog","volume":"99","author":"Staker","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026102305074360700_cit61","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1053\/j.gastro.2021.01.233","article-title":"International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma","volume":"160","author":"Singal","year":"2021","journal-title":"Gastroenterology"},{"key":"2026102305074360700_cit62","doi-asserted-by":"publisher","first-page":"8388","DOI":"10.1021\/ja204075s","article-title":"Computer review of ChemDraw Ultra 12.0","volume":"133","author":"Cousins","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"2026102305074360700_cit63","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"2026102305074360700_cit64","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"2026102305074360700_cit65","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10822-010-9352-6","article-title":"Ligand docking and binding site analysis with PyMOL and Autodock\/Vina","volume":"24","author":"Seeliger","year":"2010","journal-title":"J. Comput.-Aided Mol. Des."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01583","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/24030\/68661289\/jm6c01583.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/24030\/68661289\/jm6c01583.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:21:26Z","timestamp":1794543686000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/20\/24030\/5439017\/Design-Synthesis-and-Biological-Evaluation-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":65,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2026,9,25]]},"published-print":{"date-parts":[[2026,10,22]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01583","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01583.s006","asserted-by":"subject"}]},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}